JP2012503664A5 - - Google Patents

Download PDF

Info

Publication number
JP2012503664A5
JP2012503664A5 JP2011529154A JP2011529154A JP2012503664A5 JP 2012503664 A5 JP2012503664 A5 JP 2012503664A5 JP 2011529154 A JP2011529154 A JP 2011529154A JP 2011529154 A JP2011529154 A JP 2011529154A JP 2012503664 A5 JP2012503664 A5 JP 2012503664A5
Authority
JP
Japan
Prior art keywords
carboxylic acid
methylsulfanyl
pyridine
oxazol
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011529154A
Other languages
English (en)
Other versions
JP5507567B2 (ja
JP2012503664A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/057778 external-priority patent/WO2010036632A1/en
Publication of JP2012503664A publication Critical patent/JP2012503664A/ja
Publication of JP2012503664A5 publication Critical patent/JP2012503664A5/ja
Application granted granted Critical
Publication of JP5507567B2 publication Critical patent/JP5507567B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Description

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664

Figure 2012503664
aHPLC-MS法の合成例の項を参照されたい。
b臭素含有化合物の観察された質量は、表Iにおいて、M+およびM+2として報告されている。
またはこれらの薬学的に許容される塩。
例3:1−(4−フルオロフェニル)−1H−ピラゾロ[3,4−c]ピリジン−4−カルボン酸4−(4−メチル−ピペラジン−1−スルホニル)−ベンジルアミド(3)の合成
例9:酢酸2−{[5−({[1−(4−フルオロフェニル)−1H−ピラゾロ[3,4−c]ピリジン−4−カルボニル]−アミノ}−メチル)−ピリジン−2−スルホニル]−メチル−アミノ}−エチルエステル(9)の合成
例22:4−((S)−1−{[1−(4−フルオロフェニル)−1H−ピラゾロ[3,4−c]ピリジン−4−カルボニル]−アミノ}−エチル)−ピリジン−2−スルホン酸(22)の合成
[(S)−1−(2−メタンスルホニル−1−オキシ−ピリジン−4−イル)−プロピル]−カルバミン酸tert−ブチルエステル(1.7g、5.2mmol)のオキシ塩化リン(10mL)中の溶液を、還流で10分間加温した。次いで、混合物を複数回に分けて氷水(100mL)に添加し、30分間激しく撹拌した。次いで、溶液を飽和炭酸ナトリウムで塩基性とし、次いで酢酸エチル(4×30mL)で抽出した。合わせた有機層をブライン(2×50mL)で洗浄し、硫酸ナトリウム上で乾燥させ、真空下で濃縮すると、表題化合物が得れた。
例45:(S)−1−(2−メチルスルファニル−オキサゾール−5−イル)−プロピルアミン塩酸塩(45)の合成
2−クロロ−オキサゾール−5−カルボン酸エチルエステル(4g、22mmol)のDMF(75mL)中の溶液に、ナトリウムチオメトキシド(1.8g、25.7mmol)を添加した。混合物を50℃に加熱すると、黄色溶液が得られた。18時間後、混合物を飽和塩化アンモニウム水溶液(50mL)で希釈し、酢酸エチル(3×50mL)で抽出した。合わせた有機層をブライン(50mL)で洗浄し、硫酸ナトリウム上で乾燥させ、真空下で濃縮すると、2−エチルスルファニル−オキサゾール−5−カルボン酸エチルエステルが得られた。
2−エチルスルファニル−オキサゾール−5−カルボン酸エチルエステル(4.6g、24.57mmol)のエタノール(100mL)の溶液に、水酸化ナトリウムの2N水溶液(37mL、74mmol)を添加した。混合物を80℃で4時間加熱し、次いで真空下で濃縮してエタノールを除去した。次いで、残りの水溶液を1N HClで酸性化し、酢酸エチル(4×30mL)で抽出した。合わせた有機層をブライン(2×100mL)で洗浄し、硫酸ナトリウム上で乾燥させ、濃縮すると、2−メチルスルファニル−オキサゾール−5−カルボン酸が得られた。
例43に記載の方法と同じ方法を使用して、ワインレブアミドを介して2−メチルスルファニル−オキサゾール−5−カルボン酸を(S)−1−(2−メチルスルファニル−オキサゾール−5−イル)−プロピルアミン塩酸塩(45)に変換した。
メチルマグネシウムブロミドをエチルマグネシウムクロリドと置換した以外は、例43に記載の方法と同じ方法を使用して、ワインレブアミドを介して2−メチルスルファニル−オキサゾール−5−カルボン酸を(S)−1−(2−メチルスルファニル−オキサゾール−5−イル)−エチルアミン塩酸塩に変換した。
例43に記載の方法と同じ方法を使用して、ワインレブアミドを介して2−メチルスルファニル−オキサゾール−4−カルボン酸を(S)−1−(2−メチルスルファニル−オキサゾール−4−イル)−プロピルアミン塩酸塩に変換した。
1−(4−フルオロフェニル)−1H−ピラゾロ[3,4−c]ピリジン−4−カルボン酸[(S)−1−(2−メチルスルファニル−オキサゾール−5−イル)−プロピル]−アミド(0.1g、0.2mmol)のアセトニトリル(25mL)および水(5mL)の混合物中の溶液に、過ヨウ素酸ナトリウム(0.155g、0.725mmol)、続いて三塩化ルテニウム(5mg、0.02mmol)を添加した。6時間後、混合物を濾過し、濾液を水(50mL)で希釈し、酢酸エチル(3×50mL)で抽出した。合わせた有機層を硫酸ナトリウム上で乾燥させ、濾過して濃縮した。粗材料を酢酸エチルに溶解し、シリカのパッドに通過させた。パッドからの材料を酢酸エチル−ヘキサンから結晶化させると、表題化合物が得られた。
例46に記載の方法と同じ方法を使用して、1−(4−フルオロフェニル)−1H−ピラゾロ[3,4−c]ピリジン−4−カルボン酸[(S)−1−(2−メチルスルファニル−オキサゾール−5−イル)−エチル]−アミドを、1−(4−フルオロフェニル)−1H−ピラゾロ[3,4−c]ピリジン−4−カルボン酸[(S)−1−(2−メタンスルホニル−オキサゾール−5−イル)−エチル]−アミドに変換した。
例63:{2−(1−{[1−(4−フルオロフェニル)−1H−ピラゾロ[3,4−c]ピリジン−4−カルボニル]−アミノ}−プロピル)−5−メチル−オキサゾール−4−カルボニル]−アミノ}−酢酸メチルエステル(63)の合成

Claims (1)

  1. Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664

    Figure 2012503664
    から選択される化合物、またはその薬学的に許容される塩。
JP2011529154A 2008-09-26 2009-09-22 Ccr1受容体拮抗薬としてのアザインダゾール化合物 Active JP5507567B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10040108P 2008-09-26 2008-09-26
US61/100,401 2008-09-26
PCT/US2009/057778 WO2010036632A1 (en) 2008-09-26 2009-09-22 Azaindazole compounds as ccr1 receptor antagonists

Publications (3)

Publication Number Publication Date
JP2012503664A JP2012503664A (ja) 2012-02-09
JP2012503664A5 true JP2012503664A5 (ja) 2012-05-24
JP5507567B2 JP5507567B2 (ja) 2014-05-28

Family

ID=41349302

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011529154A Active JP5507567B2 (ja) 2008-09-26 2009-09-22 Ccr1受容体拮抗薬としてのアザインダゾール化合物

Country Status (24)

Country Link
US (4) US7879873B2 (ja)
EP (1) EP2346868B1 (ja)
JP (1) JP5507567B2 (ja)
KR (1) KR20110060904A (ja)
CN (1) CN102227425A (ja)
AP (1) AP2739A (ja)
AR (1) AR073689A1 (ja)
AU (1) AU2009296839A1 (ja)
BR (1) BRPI0919844A2 (ja)
CA (1) CA2737472A1 (ja)
CL (1) CL2011000668A1 (ja)
CO (1) CO6351735A2 (ja)
EA (1) EA201100524A1 (ja)
EC (1) ECSP11010932A (ja)
IL (1) IL210857A0 (ja)
MA (1) MA32655B1 (ja)
MX (1) MX2011002951A (ja)
NZ (1) NZ591115A (ja)
PE (1) PE20110854A1 (ja)
TW (1) TW201018683A (ja)
UA (1) UA103634C2 (ja)
UY (1) UY32140A (ja)
WO (1) WO2010036632A1 (ja)
ZA (1) ZA201100625B (ja)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134666A1 (en) 2008-04-29 2009-11-05 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
CA2722811C (en) * 2008-05-06 2016-07-05 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
AU2009296839A1 (en) 2008-09-26 2010-04-01 Boehringer Ingelheim International Gmbh Azaindazole compounds as CCR1 receptor antagonists
CA2754605C (en) * 2009-03-19 2018-04-17 Medical Research Council Technology Pyrazolopyridine compounds and their use as lrrk2 inhibitors
NZ599132A (en) 2009-10-21 2014-05-30 Boehringer Ingelheim Int Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
EP2493875B1 (en) 2009-10-27 2014-08-06 Boehringer Ingelheim International GmbH Heterocyclic compounds as ccr1 receptor antagonists
CN102596908A (zh) 2009-12-08 2012-07-18 贝林格尔.英格海姆国际有限公司 用于制备取代的吲唑和氮杂吲唑化合物的中间体的合成方法
EP2563787B1 (en) 2010-04-30 2014-11-26 Boehringer Ingelheim International GmbH Azaindazole amide compounds as ccr1 receptor antagonists
EP2388260A1 (de) * 2010-05-21 2011-11-23 Archimica GmbH Herstellungsverfahren für einen Inhibitor eines Blutgerinnungsfaktors
EP2611804A1 (en) 2010-09-03 2013-07-10 Forma TM, LLC. Novel compounds and compositions for the inhibition of nampt
EP2655371B1 (en) 2010-12-23 2015-02-25 Boehringer Ingelheim International GmbH Pyrazolopiperidine compounds as ccr1 receptor antagonists
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
CN102775365A (zh) * 2011-05-10 2012-11-14 无锡立诺康医药科技有限公司 5-氨基取代基-异噁唑类化合物或其酸式盐的合成工艺
WO2012163848A1 (en) 2011-05-27 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of crohn's disease
EP2771011A4 (en) * 2011-10-24 2015-04-15 Glaxosmithkline Ip No 2 Ltd CHEMICAL COMPOUNDS
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
JP2015508785A (ja) * 2012-03-02 2015-03-23 ジェネンテック, インコーポレイテッド ピリジニル及びピリミジニルスルホキシド及びスルホン誘導体
AR091858A1 (es) * 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
US9776996B2 (en) * 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US9045477B2 (en) * 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
FR3016879A1 (fr) * 2014-01-29 2015-07-31 Guillaume Laconde Procede de preparation de benzotriazole n-acyles
CN106103425A (zh) 2014-03-17 2016-11-09 辉瑞公司 用于治疗代谢及相关病症的二酰甘油酰基转移酶2抑制剂
JP6282759B2 (ja) 2014-04-14 2018-02-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Rorガンマのモジュレーターとしての化合物
TWI722031B (zh) 2015-10-23 2021-03-21 瑞士商威佛(國際)股份有限公司 新穎的膜鐵運輸蛋白(ferroportin)抑制劑
WO2017081312A1 (en) 2015-11-13 2017-05-18 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
EP3373732A1 (en) 2015-11-13 2018-09-19 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
US10508097B2 (en) 2016-03-07 2019-12-17 The Global Alliance For Tb Drug Development, Inc. Antibacterial compounds and uses thereof
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
CN111393376B (zh) * 2020-05-11 2022-05-13 安徽赛迪生物科技有限公司 一种2-氯嘧啶-4-甲酸的合成方法
WO2021262878A1 (en) * 2020-06-24 2021-12-30 Oregon Health & Science University Novel molecule for modulation of innate immune responses controlled by sting protein

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242931A (en) * 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
US4999363A (en) * 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
CZ289756B6 (cs) 1991-03-28 2002-04-17 Eisai Co., Ltd. Heterocyklicko-cyklické aminové deriváty, meziprodukty postupu přípravy těchto sloučenin, farmaceutický prostředek a pouľití uvedených derivátů
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
RU2105005C1 (ru) * 1992-07-03 1998-02-20 Кумиай Кемикал Индастри Ко., Лтд. Конденсированное гетероциклическое производное, способ его получения и гербицидное средство
EP0657450B1 (en) * 1993-06-25 1998-09-09 KumaiI Chemical Industry Co., Ltd. Indazolesulfonylurea derivative, use thereof, and intermediate for production thereof
CA2207201A1 (en) * 1994-12-06 1996-06-13 Caroline Henry Azetidine, pyrrolidine and piperidine derivatives as 5ht1 receptor agonists
GB9519563D0 (en) 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
GB9523583D0 (en) 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
JP2000501105A (ja) 1995-12-22 2000-02-02 デュポン ファーマシューティカルズ カンパニー 新規なインテグリン受容体アンタゴニスト
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
JPH101478A (ja) 1996-06-11 1998-01-06 Kumiai Chem Ind Co Ltd インダゾールスルホニル尿素誘導体及び除草剤
GB9615449D0 (en) 1996-07-23 1996-09-04 Merck Sharp & Dohme Therapeutic agents
CA2309175A1 (en) 1997-11-04 1999-05-14 Pfizer Products Inc. Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
WO2000076970A2 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Serine protease inhibitors
DE60022508T2 (de) 1999-06-14 2006-06-08 Eli Lilly And Co., Indianapolis Inhibitoren von serin proteasen
WO2001000656A2 (en) 1999-06-29 2001-01-04 Ortho-Mcneil Pharmaceutical, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
GB0030306D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030303D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030305D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030304D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US7058826B2 (en) 2000-09-27 2006-06-06 Amphus, Inc. System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment
US20020052373A1 (en) 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
AU2002363250A1 (en) * 2001-11-01 2003-05-12 Icagen, Inc. Pyrazole-amides and-sulfonamides
AU2002357312A1 (en) * 2001-12-20 2003-07-09 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases
ES2343787T3 (es) 2002-04-11 2010-08-10 Boehringer Ingelheim Pharmaceuticals Inc. Derivados de amidas heterociclicas de utilizacion como inhibidores de citoquina.
IL164209A0 (en) * 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
DE60328690D1 (de) * 2002-06-12 2009-09-17 Chemocentryx Inc 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen
TW200500341A (en) 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0203825D0 (sv) 2002-12-20 2002-12-20 Astrazeneca Ab Novel fused heterocycles and uses thereof
US7129264B2 (en) * 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
EP1664052B1 (en) * 2003-08-15 2009-02-18 AstraZeneca AB Fused heterocycles as inhibitors of glutamate racemase (muri)
AU2006216917A1 (en) 2005-02-24 2006-08-31 Merck Sharp & Dohme Corp. Benzazole potentiators of metabotropic glutamate receptors
GB0504828D0 (en) * 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
CA2609053C (en) * 2005-05-17 2017-04-25 Sarcode Corporation Compositions and methods for treatment of eye disorders
NZ564258A (en) * 2005-06-22 2011-02-25 Chemocentryx Inc Azaindazole compounds and methods of use
DK1924561T3 (da) 2005-09-01 2012-12-10 Lilly Co Eli 6-arylalkylamino-2,3,4,5-tetrahydro-1h-benzo[d]azepiner as 5-ht2c-receptor agonister
JP2009513677A (ja) * 2005-10-25 2009-04-02 スミスクライン・ビーチャム・コーポレイション 化合物
EP2044055A4 (en) 2006-07-21 2011-03-23 Takeda Pharmaceutical amide compounds
TW200829578A (en) * 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
EP2167497A2 (en) * 2007-06-29 2010-03-31 Sunesis Pharmaceuticals, Inc. Heterocyclic compounds useful as raf kinase inhibitors
CA2696725A1 (en) 2007-08-10 2009-03-26 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009085256A1 (en) * 2007-12-27 2009-07-09 Panacos Pharmaceuticals, Inc. Anti-hiv compounds
WO2009134666A1 (en) 2008-04-29 2009-11-05 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
CA2722811C (en) 2008-05-06 2016-07-05 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
AU2009296839A1 (en) 2008-09-26 2010-04-01 Boehringer Ingelheim International Gmbh Azaindazole compounds as CCR1 receptor antagonists
NZ599132A (en) 2009-10-21 2014-05-30 Boehringer Ingelheim Int Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
EP2493875B1 (en) 2009-10-27 2014-08-06 Boehringer Ingelheim International GmbH Heterocyclic compounds as ccr1 receptor antagonists
CN102596908A (zh) 2009-12-08 2012-07-18 贝林格尔.英格海姆国际有限公司 用于制备取代的吲唑和氮杂吲唑化合物的中间体的合成方法
EP2563787B1 (en) 2010-04-30 2014-11-26 Boehringer Ingelheim International GmbH Azaindazole amide compounds as ccr1 receptor antagonists
EP2655371B1 (en) 2010-12-23 2015-02-25 Boehringer Ingelheim International GmbH Pyrazolopiperidine compounds as ccr1 receptor antagonists

Similar Documents

Publication Publication Date Title
JP2012503664A5 (ja)
JP4859324B2 (ja) 新規環状アミド誘導体
CN101993405B (zh) 吲哚啉衍生物、及其制备方法和用途
CZ172397A3 (en) Novel benzimidazole derivatives with antihistaminic activity
CN102131792A (zh) 用于制备凋亡启动子abt-263的方法
JPH02134377A (ja) ビペリジニルベンズイミダゾール類
MXPA05003817A (es) Derivados de azaindoles como inhibidores de p38 quinasa.
WO1991009013A1 (en) Muscarinic receptor antagonists
JP2009531465A5 (ja)
JP2010521515A (ja) 新規置換アリールスルホニルグリシン、その製法及びその医薬組成物としての使用
WO2010121382A1 (en) Process for making indole cyclopropyl amide derivatives
WO2013045479A1 (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
US20100137613A1 (en) Process for eprosartan
NZ599747A (en) Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
JP2013515755A5 (ja)
JP3626191B2 (ja) 心臓血管系に活性な2−アミノ−1,2,3,4−テトラヒドロナフタレン誘導体
JP4444375B2 (ja) 新規キノリン−およびナフタレンカルボキサミド、医薬組成物およびカルパインの阻害方法
BRPI0717100A2 (pt) Derivados de pirrolizina, indolizina e quinolizina, o respectivo preparo e a respectiva aplicação em terapêutica
NO131759B (ja)
JP2002538117A (ja) 肥満の予防または治療のための医薬の製造のための多環2−アミノチアゾール系の使用
CN101311179A (zh) 制备噻吩并-苯并二氮杂卓类化合物的改进方法
EP1309577A2 (en) Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function
JP2006514978A (ja) ムスカリン受容体アンタゴニストである置換アザビシクロヘキサン誘導体
JP2002538148A (ja) 多環2−アミノチアゾール系、その製造方法およびそれを含む医薬
ES2539618T3 (es) Nuevo procedimiento de síntesis de (2E)-3-(3,4-dimetoxifenil)prop-2-enonitrilo y su utilización en la síntesis de ivabradina y sus sales de adición a un ácido farmacéuticamente aceptable.